ANI PHARMACEUTICALS, INC Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
ANI PHARMACEUTICALS, INC (ANIP) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2026-06-30 was $0.00.
- ANI PHARMACEUTICALS, INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-12-31 was -$800.00K, a 120.00% decline year-over-year.
- ANI PHARMACEUTICALS, INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-09-30 was $800.00K.
- ANI PHARMACEUTICALS, INC impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-06-30 was $0.00.
- ANI PHARMACEUTICALS, INC impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ANI PHARMACEUTICALS, INC impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $4.00M.
- ANI PHARMACEUTICALS, INC impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2023 was $0.00.
- ANI PHARMACEUTICALS, INC impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-07 | $0.00 10-Q · filed 2026-08-07 | ||
| 2025-12-31 | -$800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-08-07 | $0.00 10-K · filed 2026-02-27 |
| 2025-09-30 | $800.00K 10-Q · filed 2025-11-07 | $800.00K derived: sum of 2 quarters · filed 2026-08-07 | $800.00K 10-Q · filed 2025-11-07 | $4.80M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-07 | $0.00 10-Q · filed 2026-08-07 | $4.00M derived: sum of 3 quarters · filed 2026-08-07 | $4.00M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-08 | $4.00M derived: sum of 2 quarters · filed 2026-05-08 | $4.00M derived: sum of 3 quarters · filed 2026-05-08 | $4.00M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $4.00M derived: sum of 2 quarters · filed 2026-02-27 | $4.00M derived: sum of 3 quarters · filed 2026-02-27 | $4.00M 10-K · filed 2026-02-27 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 derived: sum of 3 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $0.00 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |